Long-Term Efficacy and Safety of Erenumab

Source : https://n.neurology.org/content/early/2021/04/28/WNL.0000000000012029.abstract

Objective To report the efficacy and safety of erenumab among episodic migraine (EM) patients who were unsuccessful on 2-4 preventive treatments observed at week 64 of Open-Label Extension Phase (OLEP) of the LIBERTY study ([ClinicalTrials.gov][1] [NCT03096834][2]).